Biosceptre key facts
as of Oct 2026- Developer of chimeric antigen receptor T-cell therapy and antibody-based immune therapeutics designed to treat cancer.
- Biosceptre is valued at approximately $431.9M as of Oct 2026 (last reported valuation).
- It has raised $52.8M; the latest was Later Stage VC ($10.9M) in Oct 2025.
- Notable investors include Innovate UK, Norcliffe Capital, Jungle Capital, McKenny-McFarlane Capital, Tuspark Science and Technology Service Group.
- Status: Privately Held (backing).
Biosceptre's last reported valuation, Feb 2024. Nothing priced has surfaced since.
- ·Watch Biosceptre: the Monday email on marks, rounds and moves
Biosceptre funding rounds
No funding rounds for Biosceptre are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
Biosceptre valuation
Biosceptre's last reported valuation was $432 million in Feb 2024. No priced round, secondary trade or fund mark has surfaced since.
Biosceptre investors
5 investors are on record for Biosceptre, including Innovate UK, Norcliffe Capital, Jungle Capital and McKenny-McFarlane Capital.
About Biosceptre
Developer of chimeric antigen receptor T-cell therapy and antibody-based immune therapeutics designed to treat cancer. The company's therapeutics develop next-generation cancer treatments targeting viruses via a range of modalities, including systemic antibodies, vaccines, and topical therapeutics, and clinical programs include systemic antibody-based therapeutics and vaccines, enabling patients to get accurate cancer treatment remedies.
- Sector
- Healthcare
- HQ
- Cambridge, United Kingdom
- Founded
- 2004
- Employees
- 16
- Website
- biosceptre.com/
- Ownership
- Privately Held (backing)
Is this your company? Sign in with your work email to keep it current, or tell us what's wrong.